journal article·2018-05-19Open access

RETRACTED ARTICLE: Intranasal delivery of quercetin-loaded mucoadhesive nanoemulsion for treatment of cerebral ischaemia

Niyaz Ahmad, Rizwan Ahmad, Atta Abbas Naqvi, Md Aftab Alam, Mohammad Ashafaq, Rehan Abdur Rub, Farhan Jalees Ahmad

This record is marked as retracted by the source. Review the publisher’s notice before using its findings.

Abstract

BACKGROUND: Quercetin (QUR), as an antioxidant flavonoid, exhibits potential role in the amelioration of cerebral ischaemia; however, poor solubility as well as oral absorption results low serum and tissue levels for this drug. PURPOSE OF THE STUDY: To enhance bioavailability, this study aims to prepare QUR nanoemulsions and administer via non-invasive nasal route in order to evaluate the drug targeting in brain. METHODS: Quercetin mucoadhesive nanoemulsion (QMNE) was prepared (ionic gelation method) and optimized using various parameters, that is, particle size, entrapment efficiency, zeta potential and ex vivo permeation study. RESULTS: The results observed for optimized QMNE were as follows: mean globule size (91.63 ± 4.36 nm), zeta potential (-17.26 ± 1.04 mV), drug content (99.84 ± 0.34%) and viscosity (121 ± 13 cp). To evaluate the extent of bioavailability for QMNE via post-intranasal (i.n.) administration, Ultra performance liquid chromatography-mass spectroscopy (UPLC-ESI-Q-TOF-MS/MS)-based bioanalytical method was developed and validated for pharmacokinetics, biodistribution, brain-targeting efficiency (9333.33 ± 39.39%) and brain drug-targeting potential (2181.83 ± 5.69%) which revealed enhanced QUR brain bioavailability as compared to intravenous administration (i.v.). Furthermore, improved neurobehavioral activity (locomotor and grip strength), histopathology and reduced infarction volume effects were observed in middle cerebral artery occlusion (MCAO)-induced cerebral ischemic rats model after i.n. administration of QMNE. CONCLUSION: This study supports a significant role for QMNE in terms of high brain-targeting potential and formulation efficiency due to ease of access and effective targeting in brain.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (Formerly University of Dammam), Dammam, Kingdom of Saudi Arabia;

Department of Pharmaceutical Chemistry, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (Formerly University of Dammam), Dammam, Kingdom of Saudi Arabia;

Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (Formerly University of Dammam), Dammam, Kingdom of Saudi Arabia;

Department of Pharmacy Practice, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University (Formerly University of Dammam), Dammam, Kingdom of Saudi Arabia;

Department of Pharmaceutics, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India;

Neuroscience and Toxicology Unit, College of Pharmacy, Jazan University, Jazan, Saudi Arabia;

Nanomedicine Lab, Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India

References (34)

Show source-provided references
1. 10.1111/j.1750-3639.1994.tb00811.x10.1111/j.1750-3639.1994.tb00811.x ↗
2. 10.1080/21691401.2016.122865910.1080/21691401.2016.1228659 ↗
3. 10.1016/j.ijbiomac.2016.03.01910.1016/j.ijbiomac.2016.03.019 ↗
4. Halliwell B · J Lab Clin Med · 1992 · 119 · 598
5. 10.2165/00002512-200118090-0000410.2165/00002512-200118090-00004 ↗
6. 10.1089/jmf.2006.9.24610.1089/jmf.2006.9.246 ↗
7. 10.1016/j.brainres.2008.10.06810.1016/j.brainres.2008.10.068 ↗
8. 10.1007/s11064-011-0458-610.1007/s11064-011-0458-6 ↗
9. 10.3892/ijmm.2011.61310.3892/ijmm.2011.613 ↗
10. 10.1002/ptr.245410.1002/ptr.2454 ↗
11. 10.2174/187460981080103016910.2174/1874609810801030169 ↗
12. 10.1016/j.ijbiomac.2016.07.00210.1016/j.ijbiomac.2016.07.002 ↗
13. 10.1002/jps.2385810.1002/jps.23858 ↗
14. 10.1016/j.ijbiomac.2016.06.00110.1016/j.ijbiomac.2016.06.001 ↗
15. 10.1186/1471-2202-9-S3-S510.1186/1471-2202-9-S3-S5 ↗
16. 10.1007/s00709-013-0516-910.1007/s00709-013-0516-9 ↗
17. 10.1016/j.jconrel.2008.02.00710.1016/j.jconrel.2008.02.007 ↗
18. 10.1088/0953-8984/18/41/R0110.1088/0953-8984/18/41/R01 ↗
19. US Food and Drug Administration. Guidance for industry: bioanalytical method validation. [cited 2014 Apr 15]. 2011. Available from: http://www.fda.gov/downloads/Drugs/GuidanceCompliance-RegulatoryInformation.Guidances/ucm070107.2011;pdf.
20. 10.1016/S0969-8051(00)00092-510.1016/S0969-8051(00)00092-5 ↗
21. 10.1161/01.STR.20.1.8410.1161/01.STR.20.1.84 ↗
22. 10.1037/0735-7044.112.5.119910.1037/0735-7044.112.5.1199 ↗
23. 10.1016/j.brainres.2009.07.02610.1016/j.brainres.2009.07.026 ↗
24. 10.1016/j.ijpharm.2005.03.02710.1016/j.ijpharm.2005.03.027 ↗
25. 10.1016/S0378-5173(01)00827-410.1016/S0378-5173(01)00827-4 ↗
26. Williams PM · 2001
27. 10.1016/S0378-5173(99)00030-710.1016/S0378-5173(99)00030-7 ↗
28. 10.1517/17425247.2012.67992610.1517/17425247.2012.679926 ↗
29. 10.2147/IJN.S3611110.2147/IJN.S36111 ↗
30. 10.1007/s11094-014-1120-910.1007/s11094-014-1120-9 ↗
31. 10.1016/j.colsurfb.2016.03.06010.1016/j.colsurfb.2016.03.060 ↗
32. 10.1021/jf304046310.1021/jf3040463 ↗
33. 10.1093/jn/135.7.171810.1093/jn/135.7.1718 ↗
34. 10.1016/j.ejpb.2008.07.00510.1016/j.ejpb.2008.07.005 ↗